Tusamitamab Ravtansine
This product is an antibody–drug conjugate (ADC) composed of a humanized IgG1 monoclonal antibody targeting CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) specifically linked to the cytotoxic maytansinoid DM4 via a cleavable disulfide linker. The antibody provides tumor specificity, while DM4 disrupts microtubule assembly, leading to targeted cancer cell death. This ADC is under investigation in clinical trials for CEACAM5-positive cancers, including non-small cell lung cancer (NSCLC).
Key Features and Benefits
-
Targeted Therapy: Directs cytotoxic payload to CEACAM5-expressing tumor cells.
-
Potent Payload: DM4 disrupts microtubules, inducing apoptosis in dividing cells.
-
Cleavable Linker: Ensures stability in circulation and payload release inside tumor cells.
-
Antibody Specificity: Humanized IgG1 reduces immunogenicity while enhancing tumor selectivity.
-
Clinical Development: Being studied for CEACAM5-positive cancers such as NSCLC.
Applications
-
Oncology Research: Investigates CEACAM5 as a therapeutic target.
-
Clinical Trials: Evaluates efficacy in NSCLC and other CEACAM5-positive tumors.
-
ADC Development: Serves as a model for designing targeted therapies.
-
Companion Diagnostics: Supports CEACAM5 biomarker testing in patient selection.
Storage and Handling
-
Storage: Store at 2–8 °C in original packaging; protect from light.
-
Handling: Do not freeze; use aseptic technique for clinical formulations.
This product combines CEACAM5-targeted antibody therapy with potent microtubule disruption, specifically representing a promising candidate for treating CEACAM5-positive cancers.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.